公开(公告)号：US20230233684A1

公开(公告)日：2023-07-27

申请号：US18054066

申请日：2022-11-09

Applicant: Hoffmann-La Roche Inc.

Inventor： Kathrin GREGORITZA ,  Andrea ALLMENDINGER ,  Satya Krishna Kishore RAVURI

IPC: A61K47/18 ,  A61K47/26 ,  A61K9/08 ,  A61K39/395

CPC classification number: A61K47/183 ,  A61K47/26 ,  A61K9/08 ,  A61K39/39591

Abstract: The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, in particular the use of certain chelators, as well as compositions and pharmaceutical products obtained with said method.

公开(公告)号：US20230227917A1

公开(公告)日：2023-07-20

申请号：US17997905

申请日：2021-05-04

Applicant: Hoffmann-La Roche Inc.

Inventor： Stephan Gasser ,  Andreas Roller

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/6869

Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determing the abundance of stem cell maintenance-related genes in a tumor tissue sample. The abundance of stem cell maintenance-related genes characterized by enhanced expressions of ASPM, CNOT3, LRPS and PBX1 predicts clinical response to the PD-L1 blockade treatment.

公开(公告)号：US20230227543A1

公开(公告)日：2023-07-20

申请号：US18193889

申请日：2023-03-31

Applicant: Hoffmann-La Roche Inc.

Inventor： Ulrich Brinkmann ,  Remko Albert Griep ,  Klaus Kaluza ,  Anita Kavlie ,  Christian Klein ,  Joerg Thoms Regula ,  Werner Scheuer

IPC: C07K16/22 ,  A61K39/00 ,  C12N15/85

CPC classification number: C07K16/22 ,  A61K39/00 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/565

Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230219953A1

公开(公告)日：2023-07-13

申请号：US18068360

申请日：2022-12-19

Applicant: Hoffmann-La Roche Inc.

Inventor： Andrew Simon Bell ,  Jérémy Besnard ,  Anthony Richard Bradley ,  Luke Green ,  Wolfgang Haap ,  Buelent Kocer ,  Andreas Kuglstatter ,  Xavier Lucas ,  Patrizio Mattei ,  Dmitry Mazunin ,  Claus Riemer ,  Willem Paul Van Hoorn

IPC: C07D471/04 ,  C07D231/56 ,  C07D209/08

CPC classification number: C07D471/04 ,  C07D231/56 ,  C07D209/08

Abstract: The present invention provides compounds of formula I




wherein X1, X2, X3, X4, R1, R1a, R1b, R2′, R2″, R3′, R3″, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

公开(公告)号：US20230212312A1

公开(公告)日：2023-07-06

申请号：US17837633

申请日：2022-06-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian KLEIN ,  Julia KRUEGER ,  Ekkehard MOESSNER ,  Jens NIEWOEHNER

IPC: C07K16/32 ,  C07K16/28 ,  C07K16/18

CPC classification number: C07K16/32 ,  C07K16/18 ,  C07K16/2881 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2317/515 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734

Abstract: The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230212277A1

公开(公告)日：2023-07-06

申请号：US18146044

申请日：2022-12-23

Applicant: Hoffmann-La Roche Inc.

Inventor： Harald Duerr ,  Frank Herting ,  Christian Klein ,  Joerg Thomas Regula ,  Matthias Rueth ,  Kay-Gunnar Stubenrauch

IPC: C07K16/22 ,  A61P27/02

CPC classification number: C07K16/22 ,  A61P27/02 ,  C07K2317/52 ,  C07K2317/31 ,  C07K2317/35 ,  A61K2039/505

Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230210856A1

公开(公告)日：2023-07-06

申请号：US18066677

申请日：2022-12-15

Applicant: Madrigal Pharmaceuticals, Inc. ,  Hoffmann-La Roche Inc.

Inventor： D. Keith HESTER, II ,  Robert J. DUGUID ,  Martha J. KELLY ,  Anna CHASNOFF ,  Gang DONG ,  Edwin L. CROW ,  Lianhe SHU ,  Ping WANG ,  Duk Soon CHOI

IPC: A61K31/50

CPC classification number: A61K31/50

Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

公开(公告)号：US20230192853A1

公开(公告)日：2023-06-22

申请号：US17640499

申请日：2020-09-03

Applicant: GENENTECH, INC. ,  F. Hoffmann-LA Roche AG

Inventor： James Thomas KOERBER ,  Alejandra Beatrice Urpi URRUTIA ,  Simon-Peter WILLIAMS ,  Christopher Williamson DAVIES ,  Shravan Kumar SRIRAMAN ,  Herman Singh GILL ,  James Richard KIEFER, Jr.

IPC: C07K16/28 ,  A61K51/10 ,  G01N33/574

CPC classification number: C07K16/2815 ,  A61K51/1027 ,  A61K51/1093 ,  G01N33/57492 ,  C07K2317/92 ,  C07K2317/569 ,  C07K2317/24 ,  C07K2317/22 ,  C07K2317/74

Abstract: Provided are CD8 binding agents comprising a VHH domain that specifically binds human CD8. Also provided are nucleic acids encoding such CD8 binding agents, vectors comprising such nucleic acids, host cells comprising same, and methods of making such CD8 binding agents. Also provided are CD8 binding agents having the VHH domain conjugated to a detectable label. Provided are methods of using such CD8 binding agents to detect CD8+ T cells, monitor disease progress, and monitor treatment progress in a subject having cancer, autoimmune disease or condition, transplant rejection or graft-versus-host disease.

公开(公告)号：US20230192623A1

公开(公告)日：2023-06-22

申请号：US17996324

申请日：2021-04-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Stefan BERCHTOLD ,  Guido GALLEY ,  Katrin GROEBKE ZBINDEN ,  Wolfgang GUBA ,  Daniel HUNZIKER ,  Daniela KRUMMENACHER

IPC: C07D231/56 ,  C07D413/06 ,  C07D401/06

CPC classification number: C07D231/56 ,  C07D413/06 ,  C07D401/06

Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.

公开(公告)号：US20230183692A1

公开(公告)日：2023-06-15

申请号：US17845592

申请日：2022-06-21

Applicant: Hoffmann-La Roche Inc.

Inventor： Lykke Pedersen ,  Souphalone Luangsay ,  Johanna Marie Walther ,  Alan James Mueller-Breckenridge

IPC: C12N15/113 ,  A61P31/20

CPC classification number: C12N15/113 ,  A61P31/20 ,  C12N2310/11 ,  C12N2310/32 ,  C12N2310/315 ,  C12N2310/341

Abstract: The present invention relates to a SEPT9 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SEPT9 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SEPT9 and capable of reducing the level of a SEPT9 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.